PR治疗慢性丙型肝炎患者营养风险的影响因素分析

发布时间：2018-04-16 19:23

  本文选题：肝炎 + 丙型　； 参考：《天津医药》2016年12期

【摘要】：目的探讨使用聚乙二醇干扰素联合利巴韦林(PR)治疗的慢性丙型肝炎(丙肝)患者出现营养风险的影响因素。方法选取接受PR治疗的慢性丙肝患者175例,测量身高、体质量,计算体质指数(BMI),用营养风险筛查2002(NRS 2002)来进行营养风险评估,并分为有风险组(140例)和无风险组(35例)。结果 2组间年龄、HCV基因型、临床类型、治疗时间及干扰素或利巴韦林是否减量差异有统计学意义(P0.05)。Logistic回归分析显示:高龄(OR值16.068,β值2.777)、干扰素减量(OR值3.096,β值1.130)、利巴韦林减量(OR值3.382,β值1.219)以及进展至肝硬化的慢性丙肝(OR值5.092,β值1.628)为营养风险的危险因素;而HCV基因型为非1b型者(OR值0.384,β值-0.957)为营养风险的保护因素。结论接受PR治疗的慢性丙肝患者营养风险发生率高。高龄、对PR不耐受、慢性丙肝进展为肝硬化的患者为发生营养风险的独立危险因素,而非1b型HCV感染者不易发生营养风险。
[Abstract]:Objective to investigate the influence factors of nutritional risk in patients with chronic hepatitis C (C) treated with peginterferon and ribavirin.Methods 175 patients with chronic hepatitis C treated with PR were selected. Height, body mass, body mass index (BMI) and nutritional risk screening (2002(NRS 2002) were measured to evaluate nutritional risk. The patients were divided into two groups: a risk group (n = 140) and a non-risk group (n = 35).Results the genotype and clinical type of HCV between the two groups were analyzed.Logistic regression analysis showed that the OR value was 16.068, 尾 value was 2.777N, OR value was 3.096, 尾 value was 1.130%, ribavirin decrement OR value was 3.382, 尾 value was 1.219) and progression to cirrhosis.The OR value and 尾 value of chronic hepatitis C were 5.092 and 1.628 respectively.The OR value of HCV genotype was 0.384, and 尾 -0.957) was the protective factor of nutrition risk.Conclusion the nutritional risk rate of chronic hepatitis C patients treated with PR is high.Elderly patients with PR intolerance chronic hepatitis C progression to cirrhosis were independent risk factors of nutritional risk but non-1b HCV patients were not susceptible to nutritional risk.
【作者单位】： 天津中医药大学公共卫生教研室;天津市第二人民医院;天津肝病研究所;
【基金】：国家科技重大专项课题(2012ZX10005004-003)
【分类号】：R512.63
，

本文编号：1760258